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 Graphical Abstract 
 
Highlights 
 Valsartan nanoparticles (50 nm) can be crystallized using a “bottom up” approach. 
 Carrier particles then help to stabilize these nanoparticles against agglomeration.  
 The drug-carrier particle composites are isolatable to dryness by simple filtration.  
 Surface optimization of the carrier particles enables higher drug loadings. 
 High drug dissolution rates from the composites are maintained up to 33 % loading.  
 
Abstract 
Drug nanoparticles are a promising solution to the challenging issues of low dissolution rates 
and erratic bioavailability due to their greater surface/volume ratio. The central purpose of this 
study is to prepare, stabilize and isolate nanoparticles of poorly water-soluble active 
pharmaceutical ingredients (APIs) into a dried form with the help of clay carrier particles. 













of aggregation and Ostwald ripening. In this study nanoparticles of the API valsartan were 
generated via a reverse antisolvent process at high supersaturations. Montmorillonite (MMT) 
and protamine functionalized montmorillonite (PA-MMT) were employed for stabilization and 
isolation of the valsartan (Val) nanoparticles (ca. 50nm) into a dried form. A high dissolution 
rate of the resultant solid formulation at high drug loadings (up to 33.3 % w/w) was achieved. 
The dissolution rates of the isolated valsartan nanoparticle carrier composites (dried Val-MMT 
nanocomposites and dried Val-PA-MMT nanocomposites) were similar to that of freshly 
prepared suspended valsartan nanoparticles, confirming that the high surface area of the 
nanoparticles is retained during the adsorption and drying processes. Differential scanning 
calorimetry and PXRD studies indicated that the valsartan nanoparticles were amorphous when 
adsorbed onto the carrier particles. The dissolution rates of the Val-MMT and Val-PA-MMT 
nanocomposites were maintained after 10 months’ storage which indicates that no aggregation 
or solid state transformation of the carrier-stabilized Val nanoparticles had occurred. 
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One of the greatest challenges in the pharmaceutical industry is to enhance the bioavailability 













(BCS), approximately 40% of drugs in the industry pipeline fall into the category of either BCS 
class II (low solubility and high permeability) or BCS class IV (low solubility and low 
permeability)1–3. Drug solubility, dissolution, and gastrointestinal permeability are the key 
determinants of oral bioavailability 3,4. Thus, the bioavailability of these drugs is limited due 
to their low solubility and slow dissolution rates. Nanoparticle formulation strategies can help 
to address the problems of low solubility5 and slow dissolution rates5,6. They have proven to 
be highly successful due to the greater surface/volume ratio of nanoparticles, resulting in an 
improvement in dissolution rate and bioavailability as well as enhanced permeability7. 
Nanoparticles can be obtained either via a “top-down” approach (the breaking of large drug 
particles by such techniques as jet milling8, pearl milling9, spiral milling media10 and high-
pressure homogenization11) or a “bottom-up”12 approach (crystallization/precipitation). 
Although the “top down” approach is used for existing nanoparticle formulations on the market, 
it has limitations such as long processing times, high energy requirements, and the risk of 
contamination in the milling/homogenization chamber. It also tends to yield a broad particle 
size distribution7. On the other hand, the “bottom-up” approach, which includes liquid 
antisolvent precipitation, is fast, simple, cost-efficient and easy to scale up13,14. However, 
nanoparticles in suspension are unstable, tending to agglomerate or to undergo Ostwald 
ripening15 to reduce their free energy16. One of the major challenges in stabilizing these 
nanoparticles in suspension lies in the identification of drug-specific crystal growth or 
aggregation inhibitors1 (soluble stabilizers). Isolation of nanoparticles from suspension to the 
dried state is crucial for their long-term stabilization and for the formulation of solid state oral 
drug delivery systems. Another major challenge in isolating these nanoparticles into the dried 
state is agglomeration during drying, again due to their high surface energy16. Current 
techniques used for isolating nanoparticles from suspension to the dried state include spray 
drying, freeze-drying or centrifugation. These techniques can be  time-consuming, difficult to 
scale up and expensive, and can adversely affect the particle size distribution14,17,18.  
There are many reports available on the use of liquid antisolvent precipitation for the generation 
of nanoparticles1. Liquid antisolvent precipitation offers very high levels of supersaturation 
which promote nucleation over particle growth, and thus generate higher numbers of 
nanoparticles. However, there are few reports on the successful isolation of these nanoparticles 
in the solid state. In 2014, Khan et al. first reported the carrier-mediated isolation of ibuprofen 
and glibenclamide nanocrystals using inert dibasic calcium phosphate as carrier particles19. 
However, the maximum drug loading on these carrier particles was very low, approximately 
0.35% (w/w), which restricts its use to potent low-dose products 19. We have previously 
reported a one-step approach for preparing, stabilizing and isolating the nanoparticles of two 
poorly water-soluble BCS class II drugs using montmorillonite (MMT) clay particles as carrier 
particles. These carrier particles serve the dual purpose of stabilizing the nanoparticles in 
suspension and thereafter allowing for their isolation via simple filtration into a dry powder 
form. In this previous study, fenofibrate and mefenamic acid nanoparticles (200-300nm) were 
isolated with MMT at 9.1 % and 4.8% w/w drug loadings respectively 20. It was necessary to 
functionalize the surface of the MMT with protamine sulfate salt (PA), a polycationic peptide21  
to prevent nanoparticle agglomeration at these loadings15. 
While MMT was observed to successfully act as a carrier particle for fenofibrate and 
mefenamic acid nanoparticles at loadings of less than 10 % w/w using PA as a surface 













system for nanoparticles of other active pharmaceutical ingredients (APIs) of different 
chemistry and particle size has not been explored20. The dissolution rates of fenofibrate and 
mefenamic acid from their respective PA-MMT nanocomposites were shown to be influenced 
by parameters such as nanoparticle size, degree of PA functionalization and drug loading on 
the carrier particle system, but the question remains as to whether these parameters are as 
relevant for smaller nanoparticles and other APIs. This study aims to compare the stability of 
API nanoparticles on MMT carrier particles in the presence and absence of soluble stabilizers 
and the surface functionalizing group PA and explores if a combination of carrier particles and 
these additives has a synergistic or counteractive effect on the isolation capability and final 
API dissolution rate.  
The model compound chosen for this study was valsartan (Val), a poorly water-soluble BCS 
class II drug (Figure 1). Valsartan belongs to the family of angiotensin II receptor antagonists 
which produce a reduction in blood pressure and is used in the treatment of hypertension22,23. 
Valsartan is a non-peptide tetrazole derivative which contains an acidic tetrazole group (pKa = 
4.73) as well as a carboxylic group (pKa = 3.9)
22. Qiuping et al. previously reported the 
production of a valsartan nanosuspension via liquid antisolvent precipitation in the presence of 
a soluble stabilizer, which was subsequently spray-dried to generate the powder form24. The 
isolated spray-dried valsartan nanoparticles showed an enhanced dissolution rate relative to 
that of “as received” valsartan, although this rate was observed to decrease slightly after six 
months’ storage, possibly because of drug recrystallization and/or agglomeration of the 
valsartan nanoparticles during this time. Using the strategy proposed in this work, valsartan 



























Valsartan (Val) ((S)-3-methyl-2-(N-{[2′-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl} 
pentanamido) butanoic acid) was generously supplied by Novartis and used as received. 
Montmorillonite K10 (MMT), Pluronic® F-127, protamine sulphate salt from salmon sperm 
(PA, approx. 5.1 kDa) and methanol (MeOH) were all purchased from Sigma Aldrich (Ireland) 
and were used as received without further purification.  
2.2 Preparation of Valsartan Form E 
14 g of valsartan powder (as received) was slurried in 100 mL of acetonitrile at 35 ⁰C for 24 h 
at 800 rpm. The resulting slurry was then filtered under vacuum; any remaining solvent was 
removed by drying in an oven at 313.15 K overnight at atmospheric pressure. 
2.3 Preparation of Nanosuspensions 
In this study, valsartan nanosuspensions were prepared by adapting the liquid antisolvent 
technique of Qiuping et al.24  In this preparation 0.5 mL of valsartan (Form E) in methanol 
solvent (100 mg/mL) was injected into 20 mL of an aqueous solution of Pluronic® F-127 (0.2% 
w/w) antisolvent under magnetic stirring (800 rpm) at 25oC.The particle size stability of the 
valsartan nanoparticles in suspension was monitored by dynamic light scattering (DLS) using 
a Malvern Zetasizer 3000 over a period of 1 month. 
2.4 Functionalization of MMT with Protamine (PA) 
Adsorption of PA onto MMT was achieved by suspending MMT carrier particles in an aqueous 
solution containing different amounts of PA under magnetic stirring (800 rpm) at 25oC and 
equilibrating for 3 h. The amount of PA was varied from 0 to 25 mg per gram of MMT to 
obtain different coating densities of PA on the MMT carrier particles in suspension. Samples 
from the resultant functionalized MMT (i.e. PA-MMT) suspensions were filtered, and analysis 
of the filtrate confirmed ca. 99% adsorption of PA in all cases.  Thereafter, these PA-MMT 
suspensions were used for the precipitation, stabilization and isolation of valsartan 
nanoparticles as described immediately below. 
Functionalization of MMT with Pluronic F-127 was achieved by suspending MMT carrier 
particles in aqueous solution containing Pluronic-F-127 (0.2 % w/w) under magnetic stirring 
(800 rpm) at 25oC and equilibrating for 3 h. The amount of MMT used was 300 mg, which was 
the same amount as in the case of the 14.28% valsartan loaded Val-Pluronic® F-127-MMT 
nanocomposites. 
2.5 Precipitation, Stabilization and Isolation of Valsartan Nanoparticles  
 The reverse antisolvent precipitation of valsartan was effected by promptly injecting a 0.5 mL 
aliquot of valsartan in methanol (100 mg/mL) into 20 mL each of the following antisolvent 
compositions: (a) an MMT suspension (25 mg/mL) in an aqueous solution of Pluronic® F-127 
(2 mg/mL), (b) an MMT suspension in water (25 mg/mL), (c) MMT suspensions (5 mg/mL) 
in an aqueous solution of  PA (containing different amounts of PA ranging from 2 to 25 mg/g 
of MMT). All antisolvent solutions/suspensions were equilibrated for 3 h at 25⁰C with 
magnetic stirring (800 rpm) before addition of the methanolic drug solution. Following the 
addition each resulting suspension was aged for 1 min and then filtered using a PTFE 
membrane (0.2µm). Aging time here refers to the time elapsed between addition of the drug 













suspension during this time. The percentage recovery of valsartan nanoparticles onto the carrier 
particles was estimated by UV Shimadzu UV-1800 UV-Visible spectrophotometer (λ=250 nm) 
by taking an aliquot of the filtrate and diluted by a factor of 10 in methanol to dissolve any 
drug particles present prior to measurement. The resultant Val-MMT and Val-PA-MMT 
nanocomposite materials were dried in a fume hood at ambient temperature and pressure for 
24 h.  
The concentration of drug in the filtrate was measured by UV Shimadzu UV-1800 UV-Visible 
spectrophotometer (λ=250 nm) by taking an aliquot of the filtrate and diluted by a factor of 10 
in methanol to dissolve any drug particles present prior to measurement. This confirmed that > 
99% of the valsartan present had adsorbed onto the MMT or PA-MMT carrier. 
2.6 In vitro drug release studies 
Dissolution tests for a nanosuspension of valsartan (50 nm), dry powder samples of Val-MMT 
and Val-PA-MMT nanocomposites, and valsartan Form E were carried out under sink 
conditions with a maximum valsartan solution concentration [Val] max of 12 mg/L
 (versus the 
corresponding equilibrium solubility, [Val] eq of 52 mg/L) in deionized water (100 mL) under 
continuous agitation (350 rpm) at 37 ± 0.5⁰C. The extent of drug dissolution was measured 
using a Shimadzu UV-1800 UV-Visible spectrophotometer (λ=250 nm) by withdrawing 1 mL 
aliquots at pre-determined time intervals (0.5, 1.5, 3, 5, 10, 15, 30, 45 and 60 min) from the 
bulk solution with a preheated plastic syringe and filtering through 0.22 µm pore preheated 
PTFE syringe filters. All measurements were carried out in triplicate. 
2.7 Particle size and zeta potential measurements 
Particle size analysis and zeta potential measurements were carried out on a Malvern Zetasizer 
Nano ZSP system using water as the dispersion medium.  A refractive index of 1.55 and an 
absorption index of 0.1 were used to measure the size of the valsartan nanoparticles. Each 
sample was equilibrated for 120 s at 250C before measurement. Ten measurements were taken 
per run and each sample was run three times. The average D50 diameter and standard deviation 
were recorded for each sample.  
The zeta potential of samples was calculated from the electrophoretic mobility by using the 
Smoluchowski approximation25. It was measured using single use capillary cells to avoid cross-
contamination between samples. Ten measurements were taken per run and each sample was 
run three times with a delay of 5 s between each run. All samples were equilibrated for 120 s 
prior to measurement, and all measurements were made at 250C. 
Particle size analysis of recrystallized valsartan Form E was determined using a Malvern 
Morphologi G3SE particle characterisation system (Malvern Instruments, Malvern, UK). 
Samples were dry dispersed using the system’s automated sample dispersion unit (5541 mm2 
area) onto a glass plate (180X110 mm) with an injection pressure of 4.0 bar, the injection time 
of 10 ms and setting time of 60 seconds. A range of particle size from 0.5µm-40µm were 
quantified using 50X (Nikon TU plan ELWD) magnification optics selection. The system 
works by imaging every particle and as such reports a number-based particle size distribution. 
2.8 Powder X-ray Diffraction (PXRD) 
Reflection powder X-ray diffractograms (PXRDs) was recorded using an Empyrean 













kV and 40 mA at room temperature. Samples were scanned from 5 to 50° (2θ) with 0.026° 
2θ/min step size and 112.97 s per step, on a flat stage that was spinning at 4 rpm. 
2.9 Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was carried out under a nitrogen environment (30 
mL/min) using a PerkinElmer instruments Pyris 1 DSC in the range 30 to 170°C at scan rates 
of 10°C/min. Experiments were carried out using platinum pans with pinholes (as 
manufactured), sealed by a crimping press. The instrument was calibrated using samples of 
indium and lead. 
2.10. Stability Tests 
To investigate the stability of the nanocomposites over time, samples of Val-MMT and Val-
PA-MMT (all in dry solid form) were stored in closed glass vials on an open laboratory bench 
at room temperature for 10 months. After this time, the samples were analysed via DSC and 
PXRD, and in vitro drug release studies were also performed.   
 
3. Results: 
3.1 Particle size and particle size stability of the valsartan nanoparticles produced via 
reverse antisolvent precipitation 
Valsartan particles of 50 ± 0.4 nm were obtained in the presence of Pluronic® F-127 (as a 
soluble stabilizer of the drug particles) Figure 2. The particle size distributions of these 
nanoparticles remained stable in suspension over a period of 30 days when Pluronic® F-127 
was used (Figure 2).  
However, when produced in the absence of Pluronic® F-127, the valsartan nanoparticles were 
observed to aggregate/grow from 50 nm initially to > 1 m after 30 minutes, Figure 3. The 
Pluronic® F-127 stabilized nanoparticles (50 nm) could not be isolated by simple filtration 
because they passed through or blocked the filter (0.22 µm pore size) due to their small size. 
Hence, as outlined in the section immediately below, the MMT carrier particle system was used 
with the aim of stabilizing these nanoparticles in a solid form that was amenable to isolation 
via simple filtration. 
3.2 Attachment of Valsartan Nanoparticles produced via reverse antisolvent precipitation 
to the MMT or PA-MMT Carrier Particles 
The attachment of the valsartan nanoparticles produced via reverse antisolvent precipitation 
onto the MMT or PA-MMT carrier particles was confirmed by the clear filtrate obtained after 
filtration of the related nanosupsensions through 0.22 µm PTFE membrane filters (Scheme 1 
– lower path). The concentration of drug in the filtrate was measured by UV Shimadzu UV-
1800 UV-Visible spectrophotometer (λ=250 nm) by taking an aliquot of the filtrate and diluted 
by a factor of 10 in methanol to dissolve any drug particles present prior to measurement. This 
confirmed that > 99% of the valsartan present had adsorbed onto the MMT or PA-MMT carrier. 
Stabilized nanosuspensions filtered in the absence of MMT carrier particles passed through the 
0.22 µm PTFE membrane filter resulting in a milky filtrate (Scheme 1 – upper path). When 













particles, almost complete (>99%) adsorption of the valsartan nanoparticles at a maximum drug 
loading of 33.3% w/w was achieved without the need to include  Pluronic® F-127 as a soluble 
stabilizer. The percentage recovery of nanoparticles onto MMT or PA-MMT carrier particles 
decreased from 99% to 88% when the valsartan loading was increased from 33.3% to 40% 
w/w. 
For nanocomposites formed with MMT and Pluronic® F-127, and at valsartan nanoparticle 
loadings greater than 9.1%, there was a pronounced decrease in the percentage recovery of 
nanoparticles and a milky filtrate was obtained. It was also found that the surface charge of 
MMT increased from -30.7 ± 0.14 to -0.08 ± 0.01 mV when MMT was incubated with F127, 
supplementary information, Figure S3. Thus, the presence of Pluronic® F-127 reduced the 




3.3 Dissolution behavior of the variously prepared Nanodrug-Carrier Composites 
After filtration and drying, the variously prepared dried nanodrug-carrier composites (hereafter 
referred to as nanocomposites (NCs)) were suspended in de-ionised water and the related 
dissolution profiles of valsartan were measured. The results are presented in Figure 4 for 
samples with valsartan loadings in the range 9 to 33.3 % w/w. For comparison purposes this 
figure also includes the dissolution profiles for (i) Valsartan Form E (particle size ~11µm, see 
Supplementary information, Figure S1) and (ii) 50 nm valsartan particles from a freshly 
prepared nanosuspension. The first observation is that all NCs samples (whether prepared in 
the presence or absence of Pluronic® F-127) exhibited a more desirable valsartan dissolution 
profile than that of valsartan Form E, Figure 4 (a) and (b). For NCs samples prepared in the 
presence of Pluronic® F-127, the dissolution profile for valsartan from 9% w/w loaded dried 
Val-MMT-F127 was comparable with that of the freshly prepared valsartan 50 nm 
nanosuspension, although this comparison became less favourable as the valsartan loading 
increased to ca. 14 % w/w and above. By contrast, the dissolution profiles for valsartan from 
dried Val-MMT NCs samples prepared in the absence of Pluronic® F-127 were comparable 
with that of the valsartan 50 nm nanosuspension for drug loadings up to 20% w/w. The trend 
in terms of loading and dissolution rate is not consistent in the range of 9 – 20 % w/w loading 
but the release profiles are comparable. However above 20 % w/w, a distinct reduction in the 
rate of release is observed when the loading was increased to 33 % w/w. 
The particle size of the drug in the Val-MMT-F127 (9% w/w valsartan) and the Val-MMT (20 
% w/w valsartan) nanocomposite samples can be considered broadly similar to that of the drug 
nanoparticles in the nanosuspension (50 nm) because of the comparable dissolution profiles 
amongst all three samples; this indicates that both of these NC formulations likely possess 
similar available surface areas for dissolution up to the stated valsartan loadings. The somewhat 
poorer valsartan dissolution profiles observed for the NC samples above these stated loadings 













In one series of experiments valsartan nanoparticles were prepared via reverse antisolvent 
precipitation in the presence of the stabilizer Pluronic® F-127 but MMT was only added after 
the precipitation of the valsartan was complete. In this experiment the valsartan loading was 
9.09 % w/w. Figure 5 compares the corresponding dissolution profile for valsartan from the 
resultant dried Val-MMT-F127 nanocomposite with that for the valsartan 50 nm 
nanosuspension. The very similar dissolution profiles for both samples is consistent with a 
mechanism whereby valsartan precipitates at the high supersaturations generated during the 
reverse antisolvent process to form nanoparticles stabilized by the Pluronic® F-127 which then 






3.4 Charge modification of MMT with PA 
The relative disimprovement in valsartan’s dissolution profile from the dried Val-MMT 
nanocomposite at 33.3 % w/w loading likely indicates that some aggregation of the valsartan 
nanoparticles was occurring on the surface of the carrier particles. Therefore, to improve the 
dissolution profile at this higher drug loading, the surface charge properties of the MMT carrier 
particles were modified by the adsorption of Protamine (PA) prior to the reverse antisolvent 
precipitation step. In a previous study, using MMT with a PA surface coverage of 4.6 mg/g 
during the reverse antisolvent precipitation of fenofibrate and mefenamic acid proved effective 
in enhancing these APIs’ dissolution profiles from their respective API-PA-MMT 
nanocomposites20.  
The zeta potentials of freshly prepared valsartan nanoparticles, the Val-MMT nanocomposite 
(9.09% w/w loading) and unmodified MMT were measured to be -42.5 ± 1.37 mV, -29.2 ± 
1.41 mV and -30.7 ± 0.14 mV respectively in aqueous media. After the adsorption of varying 
amounts of PA from 2 to 25 mg/g of MMT, the surface charge of the PA-MMT particles 
changed from -30.1 ± 0.40 to 16.9 ± 0.25 mV (Supplementary information, Figure S2). The 
zeta potential of the carrier was dependent on the coating density of PA on the MMT surface 
and was easily tuned by varying the levels of adsorbed PA (Figure 6).  
The PA-MMT carrier particles also adsorbed over 99% of the valsartan nanoparticles at the 
maximum drug loading of 33.3% w/w in the absence of Pluronic® F-127. The dissolution 
profiles of valsartan from Val-PA-MMT (33.3% w/w loading) with different surface coverages 
of PA are shown in Figure 7. 
3 mg/g of MMT at a 33.3 % w/w valsartan loading was found to be the optimum PA coverage 
to give a dissolution profile that was comparable with that of a freshly prepared valsartan 50 
nm nanosuspension. This is a much higher API loading than the previously reported, at 9.1 and 
4.8 % w/w loadings for fenofibrate and mefenamic acid respectively20.  
The effect of PA loading on valsartan’s initial dissolution rate from the resultant series of Val-













3.5 Stability of Val-MMT and Val-PA-MMT nanocomposites 
After storage for ten months at ambient temperature, Val-MMT and Val-PA-MMT 
nanocomposites displayed valsartan dissolution profiles (Figure 9) comparable with those of 
freshly prepared Val-MMT and Val-PA-MMT nanocomposites. This suggests that no 
recrystallization/aggregation of the valsartan nanoparticles has occurred during this time, 







3.6. Solid state characterization 
The powder XRD pattern of unprocessed valsartan Form E showed characteristic high intensity 
diffraction peaks, as did the pattern for a 33.3 % w/w physical mixture of Val Form E and 
MMT, Figure 10 (a). However, no characteristic diffraction peaks were observed in any of a 
selection of variously loaded Val-MMT nanocomposites, suggesting that the drug 
nanoparticles therein were amorphous.  
DSC analysis was therefore undertaken to further investigate the physical state of the valsartan 
nanoparticles adsorbed onto the MMT carrier particles. The thermogram of unprocessed 
valsartan Form E showed an endothermic peak at 138.4 ± 0.4⁰C corresponding to its melting 
temperature, while the corresponding thermogram of its 33.3 % w/w physical mixture with 
MMT gave a similar profile. However, the melting peak of valsartan was not detected in any 
of the thermograms of a selection of variously loaded Val-MMT and Val-PA-MMT 
nanocomposite samples; these included a 33.3% w/w loaded sample which had been stored at 
room temperature for 10 months, suggesting that the adsorbed valsartan nanoparticles had not 
undergone a crystalline transformation during this time (Figure 10 (b)).  
4. Discussion: 
Carrier particle mediated isolation of nanoparticles is a very straightforward and facile method 
to stabilize and isolate nanoparticles using simple filtration and drying. Drug nanoparticle 
loading depends upon several factors such as the accessible surface area, size and surface 
charge of the carrier particles, functional group complementarity and nanoparticle-carrier 
particle interactions26. In this study valsartan nanoparticles formed by reverse antisolvent 
precipitation at high supersaturations attach to MMT and PA-MMT carrier particles. The 
resulting Val-MMT and Val-PA-MMT nanocomposites can be isolated from the suspension as 
stable solids by simple filtration followed by air-drying. In all cases studied, almost complete 
adsorption (>99%) of valsartan nanoparticles to MMT or PA-MMT carriers was observed 
irrespective of these carrier particles zeta potentials.  From this study, it has been shown that 
the PA-MMT carrier particle system facilitates the isolation of valsartan nanoparticles for drug 













that of freshly prepared valsartan nanosuspensions (50 nm). This loading is over three times 
higher than that previously achieved during the earlier related study with fenofibrate and 
mefenamic acid20. A significant disimprovement in valsartan’s percentage recovery and 
dissolution profile (above 9.09% w/w loading) was observed for valsartan nanocomposites 
formed with MMT and Pluronic® F 127, instead of with MMT or MMT treated with PA alone. 
Thus, a negative influence on valsartan’s isolation and dissolution profile is observed in the 
presence of the soluble stabilizer Pluronic® F 127. This might be due to the inadvertent 
interaction of Pluronic® F 127 with MMT to form a polymer-clay composite whose surface 
area is then less receptive to adsorbing valsartan nanoparticles27,28.  This hypothesis is 
supported by the observed change in MMT’s zeta potential from -30.7 to -0.08 mV 
(Supplementary information, Figure S3) following its suspension in a solution of Pluronic® 
F 127; this is likely due to the latter’s adsorption onto the MMT’s outer surface.       
There have been several reports of drug intercalation in MMT whereby drug molecules have 
been adsorbed into the inter layers of MMT clays29–34. However, the valsartan nanoparticles 
produced during this study are much larger in size (50 nm) than the distance between the layers 
of MMT (0.9 to 1.2 nm), thus restricting their adsorption onto MMT’s outer surface. As such, 
the valsartan nanoparticles’ predominant surface residency likely contributed to the drug’s 
prompt dissolution from the Val-MMT and Val-PA-MMT nanocomposites. Both types of 
valsartan nanocomposites exhibited excellent dissolution rates, with more than 90% of drug 
dissolving in less than 10 minutes. This compares favorably with the dissolution profiles for a 
number of other intercalated drug-MMT composites aforementioned27-32. For example, Joshi 
et al. have reported that less than 50% of timolol maleate dissolved after 8 h from a sample of 
the drug intercalated in MMT29. The surface of MMT is characterized by protrusions of polar 
hydroxyl groups (–OH) and hydrophobic siloxane groups (Si–O–Si), leaving it negatively 
charged due to the absence of nearby isomorphic cation substitution35–37. However, despite also 
being negatively charged, the valsartan nanoparticles still adsorb onto the negatively charged 
MMT carrier particles. Adsorption is therefore potentially due to hydrophobic interactions 
between the aliphatic and/or aromatic groups of valsartan and the siloxane groups 38 present on 
the MMT surface36,37,39.  
Drug dissolution profiles comparable with that for valsartan nanosuspensions (50nm) were 
obtained at Val-MMT drug loadings of up to 20% w/w. Above this loading, and when in the 
absence of PA, the valsartan nanoparticles started aggregating on MMT’s surface, which 
adversely impacted their ability to dissolve. However, with the help of PA to reduce the 
unfavourable electrostatic interactions between MMT and the valsartan nanoparticles, 
dissolution profiles comparable with that of the nanosuspension were maintained up to a drug 
loading of 33.3% w/w. These findings compare favourably with those from our earlier related 
study on fenofibrate where such dissolution-hindering aggregation occurred at a much lower 
drug loading of 9.1 % w/w. This difference in aggregation/dissolution profiles may simply be 
due to the larger particle size of fenofibrate’s isolated nanoparticles (200 to 300 nm diameter) 
relative to that of valsartan’s (50 nm diameter), whereby the impact of even moderate levels of 
nanoparticle aggregation would likely be more pronounced in the case of the larger fenofibrate 
nanoparticles. Furthermore, MMT does not present a smooth surface, and the smaller valsartan 
nanoparticles may have comparatively better access than the larger fenofibrate particles to the 













more nanoparticles of a smaller size may account for the higher stabilization capacity of MMT 
for valsartan over fenofibrate. 
Clearly, the introduction of charged adsorption sites on the MMT surface proved beneficial in 
limiting the formation of drug nanoparticle aggregates in favour of a more homogeneous 
segregation of the nanoparticles on the carrier particles. This was done by modifying the charge 
on the MMT carrier particles using positively charged PA20, and the extent of PA’s coating 
density was seen to greatly influence valsartan’s initial dissolution rate from 33.3% w/w Val-
PA-MMT nanocomposites.  This may be inferred from Figure 8 where optimum dissolution 
coincided with a carrier particle zeta potential of -27.7 mV (at 3 mg of PA/g of MMT) versus 
ca. -40 mV for the valsartan nanoparticles. In this study, and those previously undertaken for 
fenofibrate and mefenamic acid20, the optimal PA coverage on MMT was between 2 and 5 
mg/g MMT, and PA-MMT carrier particles have been shown capable of acting as a generic 
stabilizer and nano-isolator for all three APIs. The zeta potentials of the three APIs are similar 
(-30 to -40 mV)20,which may explain the similar optimal surface coverage of PA among them. 
In all three cases studied, this rather sparse coating of PA on MMT appears enough to introduce 
a sufficient number of favourable adsorption sites on MMT’s surface for the homogeneous 
segregation of drug nanoparticles to occur, thus producing such promising initial dissolution 
rates. 
Our previously proposed model for MMT describes the presence of zones on its surface which 
are negatively charged and other zones which are hydrophobic. Therefore, its surface will 
become less negatively charged as evermore PA is introduced. However, at higher PA coating 
densities, a negative impact on valsartan’s dissolution profile was seen. This was due to the 
accumulation of positively charge PA on MMT’s surface, around which the valsartan 
nanoparticles clustered, leading to aggregation. Conversely, valsartan’s dissolution profile also 
suffered at lower PA coating densities, indicating that the nanoparticles were most likely 
aggregating on the MMT’s hydrophobic adsorption sites to avoid its negatively charged sites. 
The PA-MMT zeta potential of -25 to -28 mV seems to represent an optimum range whereby 
the valsartan nanoparticles can attach to PA-MMT in a manner which minimized aggregation. 
Further studies are being conducted to establish whether API nanoparticles with different zeta 
potentials necessitate different coating densities of PA. 
5. Conclusion 
In summary, nanoparticles of valsartan (50 nm) have been prepared, stabilized and isolated on 
protamine-functionalized MMT carrier particles in a dried form, with a high dissolution rate at 
high drug loadings (33.3 % w/w) and exhibiting long-term stability. PA-MMT can thus act as 
a generic carrier particle system to enable the stabilization and isolation of API nanoparticles 
following their reverse antisolvent precipitation from solution. For API nanoparticles with a 
zeta potential in the range of -30 to -40 mV, it appears that a PA surface coverage of 3 to 5 
mg/g MMT helps to limit the extent of nanoparticle aggregation and thus enhance the API’s 
dissolution profile. From this study it has been found that smaller nanoparticles enable higher 
drug loadings without any decrease in dissolution rate. The high drug nanoparticle loading 
obtained in this study offers a potentially effective means of formulating relatively potent low-
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Figure 2. Particle size distributions of valsartan nanoparticles (50 nm) in nanosuspensions 
obtained following reverse antisolvent precipitation in the presence of Pluronic F 127 after 2 





















Figure 3. Change in the particle size distribution of valsartan nanoparticles in the absence of 














Figure 4. Comparison of the dissolution profile for valsartan Form E with those for valsartan 
from the following formulations in de-ionised water at 37oC: (a) valsartan nanosuspension, 
and dried Val-MMT nanocomposites (NCs) with different valsartan loadings (% w/w), and (b) 

















Figure 5. Comparison of the dissolution profile for valsartan Form E in de-ionised water at 
37oC with those for the following formulations: (i) valsartan nanosuspension and (ii) dried 
Val-MMT-Pluronic® F-127 nanocomposite (NCs) at 9.09% w/w valsartan loading prepared 
















Figure 6.The influence of varying levels of adsorbed PA (in mg/g MMT) on the zeta potential 
of the corresponding PA-MMT particles.  
 
 
Figure 7. Dissolution profiles of Val-PA-MMT nanocomposites (each 33.3% w/w loading) at 















Figure 8. The variation in the initial dissolution rate of valsartan from 33.3% w/w loaded Val-
PA-MMT nanocomposites characterized by different zeta potentials arising from the indicated 
surface coverages of PA in mg/g of MMT. The initial dissolution rate is defined as the % of the 















Figure 9. Comparison of the valsartan dissolution profiles of (a) freshly prepared dried Val-
MMT nanocomposites with 10 month old Val-MMT nanocomposites, and (b) freshly prepared 

















Figure 10. (a) PXRD patterns of valsartan Form E (experimental and from the CSD), a 33.3% 
w/w physical mixture of valsartan and MMT, MMT, and a selection of valsartan nanoparticle-
MMT composites with different valsartan loadings (%w/w), and (b) DSC profiles of valsartan 
Form E, a 33.3% w/w physical mixture of valsartan and MMT, a selection of valsartan 
nanoparticle-MMT composites with different valsartan loadings (%w/w) including a sample 
stored at room temperature for 10 months, and MMT. 
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Scheme 1: Production and isolation of valsartan nanoparticles in the presence of (i) Pluronic® 
F-127 (upper path), and (ii) MMT or PA-MMT carrier particles (lower path). 
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